Heat Exposure and Cause-Specific Disease Burden Across Climate Vulnerability Strata: A Longitudinal Panel Analysis of 187 Countries with Future Projections to 2050
Challenges · 29.06.2026 · 17 (3) · 22
DOI: 10.3390/challe17030022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Challenges, online erschienen am 29.06.2026. Verfasst von Hanif Abdul Rahman und 2 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Heat exposure is a leading climate-related health threat, yet whether the heat–disease burden relationship is moderated by national adaptive capacity remains poorly quantified at the global level. We examined associations between heat exposure and cause-specific disability-adjusted life year (DALY) burden across climate vulnerability strata and projected future burden to 2050 under IPCC AR6 warming scenarios.
Methods
We constructed a country–year panel spanning 187 countries and 34 years (1990–2023) by merging ERA5 reanalysis temperature data; GBD 2023 DALY rates for cardiovascular diseases (CVD), chronic kidney disease (CKD), and chronic respiratory diseases (CRD); ND-GAIN adaptive-capacity scores; and WHO GHO health system indicators. Countries were stratified into adaptive-capacity tertiles (Low: n = 63; Medium: n = 62; High: n = 62). We used two-way fixed-effects panel regression with country-clustered standard errors, a formal Chow test of slope equality, lagged exposure models, and a benefit-of-adaptation counterfactual. Future DALY burden was projected to 2030, 2045, and 2050 using country-specific ERA5 warming trends scaled to IPCC AR6 SSP scenario multipliers.
Findings
The heat–CVD dose–response was 26 times larger in Low versus High adaptive-capacity countries (β = −346.2 vs. −13.1 DALY years per 100,000 per °C). The Chow test confirmed statistically significant slope heterogeneity across tertiles for all three outcomes (CVD: F = 22.0, p < 0.0001; CKD: F = 14.9, p < 0.0001; CRD: F = 9.4, p < 0.0001). CKD burden rose 47·8% globally between 1990 and 2023, with the strongest within-country heat–CKD association in Medium adaptive-capacity countries (β = −61.5, p < 0.0001). These findings were robust to lagged exposure specifications. Under SSP5-8.5 by 2050, Low adaptive-capacity countries face a projected CVD DALY rate change 23 times larger than High adaptive-capacity countries (−16.2% vs. −0.7%). Upgrading Low adaptive-capacity countries to High tertile standards would avert 15.6% of projected CVD DALY burden under SSP5-8.5 by 2050.
Conclusions
Adaptive capacity substantially moderates the health consequences of heat exposure. The quantified benefit of adaptation investment—expressed as averted DALY burden—provides a direct metric for health-system strengthening and climate adaptation financing, particularly in low-income settings facing the steepest projected burden increases. These results position adaptive capacity as a critical social determinant of planetary health, linking Earth-system boundary transgression to inequitably distributed human disease burden across the global community.
Zitieren
APA
Rahman, H. A., Suhaimei, U. S., & Tun, H. M. (2026). Heat Exposure and Cause-Specific Disease Burden Across Climate Vulnerability Strata: A Longitudinal Panel Analysis of 187 Countries with Future Projections to 2050. Challenges, 17(3), 22. https://doi.org/10.3390/challe17030022
Vancouver
Rahman HA, Suhaimei US, Tun HM. Heat Exposure and Cause-Specific Disease Burden Across Climate Vulnerability Strata: A Longitudinal Panel Analysis of 187 Countries with Future Projections to 2050. Challenges. 2026;17(3):22. doi:10.3390/challe17030022
BibTeX
@article{Rahman2026,
author = {Rahman, Hanif Abdul and Suhaimei, Ummi Salwa and Tun, Hein Minn},
title = {Heat Exposure and Cause-Specific Disease Burden Across Climate Vulnerability Strata: A Longitudinal Panel Analysis of 187 Countries with Future Projections to 2050},
journal = {Challenges},
year = {2026},
volume = {17},
number = {3},
pages = {22},
doi = {10.3390/challe17030022}
}
EUVIMED